BioSpace News Archive

Addiction to a substance or a habit exists in a variety of forms – drug addiction, alcohol addiction, and food addiction, to name a few. Addiction habits literally might tear down a person’s life if not controlled in the early stages.

Internationally Known Eye Cancer Researcher and Clinician Joins Newest NCI-Designated Cancer Center and Nation’s Top-Ranked Eye Hospital

BURNABY, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed on January 27, 2020, have exercised in full their option to purchase an additional 562,500 common shares at the public offering price of $16.00 per share, raising additional gross proceeds of $9.0 million and increasin

Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models WALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced an oral presentation today highlighting Morphic’s product candidate MO

Following the 2019 novel coronavirus outbreak, WeSure, Tencent’s insurance platform, swiftly established an emergency response team to provide real-time information to users, and introduced multiple insurance plans designed to protect those who may be affected.

symplr, a leading healthcare governance, risk and compliance (“GRC”) software-as-a-service (“SaaS”) platform, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) and SkyKnight Capital (together with its affiliates, “SkyKnight”), today announced that it has acquired The Patient Safety Company (“TPSC”) from Main Capital Partners (“Main”). Financial terms were not disclosed.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM)(“Zomedica” or “Company”), a veterinary diagnostic company, announced today the completion of its previously announced registered direct offering of 20,833,334 of its common shares at a purchase price of $0.12 per share, for gross proceeds of $2.5 million.

The FDA plays an essential role in overseeing our Nation’s medical products as part of our vital mission to protect and promote public health, including during public health emergencies.

The incidence of cancer has increased tremendously in the past few years. With advancements in science and technology, the treatment for cancer has become efficient and affordable

The global market for Life Science Microscopy Devices has an extremely consolidated vendor landscape wherein the leading four companies account for nearly 90% of the overall market in 2016, observes Transparency Market Research in a recent report.